Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT afte...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

KRd consolidation in MM patients with a positive PET-CT after standard first-lin...

Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse ...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

Myeloma highlights from EHA 2019

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )

AlloHCT conditioning intensity in AML in complete remission with residual diseas...

Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, U...

AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth ...

Prof Philippe Moreau - Chu Nantes, Nantes, France

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety ( Prof Philippe Moreau - Chu Nantes, Nantes, France )

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lu...

Intervention for AML patients with MRD can result in improved survival ( Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA )

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital an...

Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks - University Hospital Bristol, Bristol, UK

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse ( Prof David Marks - University Hospital Bristol, Bristol, UK )

More from ecancer